Division of Pharmaceutical Sciences, University of Missouri-Kansas City, Kansas City, MO 64108-2718, USA.
J Ocul Pharmacol Ther. 2013 Mar;29(2):106-23. doi: 10.1089/jop.2012.0200. Epub 2012 Dec 5.
Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.
制药科学的研究进展带来了前节段药物输送的新策略。设计一种新的给药系统，能够有效地靶向患病的前眼部组织，产生高药物水平，并保持长时间有效的浓度，没有或最小的副作用，是当前研究的主要焦点。通过传统的局部给药方式进行药物输送会受到眼部静态和动态屏障的阻碍。已经有各种产品被引入市场，以延长药物在角膜前囊中滞留时间并提高生物利用度。然而，需要有一种给药系统，能够以减少给药频率的方式提供控制释放，以治疗慢性眼部疾病，而不会引起任何视觉障碍。本综述概述了前眼部屏障以及克服这些眼部屏障的策略，并特别强调了基于纳米技术的药物输送方法，以将治疗剂递送到受影响的前眼部组织。
